engineered tcr and car immunotherapeutics 2015

10
www.MarketResearchReports.com Engineered TCR and CAR Immuno therapeutics 2015 Category : Pharma & Healthcare All logos and Images mentioned on this slide belong to their respective owners.

Upload: market-research-reports-inc

Post on 24-Jul-2015

124 views

Category:

Healthcare


2 download

TRANSCRIPT

Page 1: Engineered TCR and CAR Immunotherapeutics 2015

www.MarketResearchReports.com

Engineered TCR and CAR

Immuno therapeutics

2015

Category : Pharma & Healthcare

All logos and Images mentioned on this slide belong to their respective owners.

Page 2: Engineered TCR and CAR Immunotherapeutics 2015

www.MarketResearchReports.com

Introduction to Report

Launch Date: March 16, 2015

Number of Pages: 201

Geography Coverage: Global

Available Format: PDF

Price For Single User License: USD 2,630

Price For Site User License: USD 4,991

Price For Global User License: USD 7,892

Delivery Time: Within 24 Hours (During Working Days)

Page 3: Engineered TCR and CAR Immunotherapeutics 2015

www.MarketResearchReports.com

About the Report

This report „Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & DLIs“ as of March 2015 brings you up-to-date regarding key players, key technologies, TCR and CAR immunotherapeutic projects, business deals and private and public financing rounds.

Page 4: Engineered TCR and CAR Immunotherapeutics 2015

www.MarketResearchReports.com

Key Findings:

Page 5: Engineered TCR and CAR Immunotherapeutics 2015

www.MarketResearchReports.com

Key Findings: Continues…

The report analyzes the TCR and CAR immunotherapeutic pipelines and stakeholders in the field, especially among Big Pharma/Biotech and technology companies.

The report highlights the value of TCR and CAR immunotherapeutics in terms of partnering economic conditions, private financing rounds and (initial) public offerings with the resulting market capitalization of companies.

However, progress in clinical trials and supply of clinical grade batches reveals some major limitations which need to be surmounted and the problems solved if TCR and CAR immunotherapeutics want to become commercially viable and successful products.

This report describes the challenges and limitations and identifies solutions provided by new technologies which offer tremendous business opportunities.

Page 6: Engineered TCR and CAR Immunotherapeutics 2015

www.MarketResearchReports.com

Key Findings: Continues…

This report has been built in a bottom-up basis by desktop search to identify and describe company, product, technology and business/financing profiles which then are evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities.

The engineered T cell receptor (TCR) for targeting of intracellular targets not druggable by conventional antibody technologies, and specifically targeted engineered T cells are two of the most promising emerging technologies in immuno-oncology apart from immune checkpoint modulators.

The relevance of TCR targeting and engineered T cells is reflected by impressive clinical results with CD19 chimeric antigen receptor (CAR) T cells and outstanding partnering and financing deals concluded within the last two years.

Page 7: Engineered TCR and CAR Immunotherapeutics 2015

www.MarketResearchReports.com

Report Coverage:

1. Introduction

2. Executive Summary

3. Profiles of TCR & CAR Immunotherapeutics, NK Cells, TILs, DLIs and CTLs

4. Pipeline Analysis

5. Technology Companies

6. Pharmaceutical Companies

7. Stakeholder Analysis

8. Selected Technology Profiles

9. Business Perspective on TCR and CAR Immunotherapeutics

10. Outlook for TCR and CAR Immunotherapeutics

For more details regarding Report coverage see the last slideAll logos and Images mentioned on this slide belong to their respective owners.

Page 8: Engineered TCR and CAR Immunotherapeutics 2015

www.MarketResearchReports.com

Company Coverage: (Partial List)

1. Adaptimmune

2. Altor Biosciences

3. Amgen

4. Applied Immune Technologies

5. AstraZeneca

6. Autolus

7. Bellicum Pharmaceuticals

8. Bluebird bio

9. Cardio3 BioSciences

10. Celgene

For more details regarding Report coverage see the last slide

All logos and Images mentioned on this slide belong to their respective owners.

Page 9: Engineered TCR and CAR Immunotherapeutics 2015

www.MarketResearchReports.com

Custom Research: Are you an industry professional, entrepreneur,

venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research.

For Any Customization Related query Visit IdeaCenter @http://www.marketresearchreports.com/idea-center

For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter

Page 10: Engineered TCR and CAR Immunotherapeutics 2015

www.MarketResearchReports.com

How To Buy This Report?

Visit following URL to see Table of Content and purchase this publication:

http://mrr.cm/4GD

About Market Research Reports, Inc.Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”.

Contact : Amitava SenEmail : [email protected]: +1 302-703-7787 (USA) +91-8762746600 (India)